

Changing the Paradigm in Prognostic Breast Cancer Testing Based on Extracellular Vesicles

Malgorzata A. Witek^{1,2,3*}, Steven A. Soper⁴, Andrew K. Godwin^{2,3,5}

¹Department of Chemistry, The University of Kansas, Lawrence, KS 66047, USA

²Center of Bio-Modular Multiscale Systems for Precision Medicine (CBM2), The University of Kansas, Lawrence, KS 66047, USA

³Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA

⁴Department of Cancer Biology, The University of Kansas Medical Center, Cancer Center, Kansas City, KS 66160, USA

⁵Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA

Commentary

Received: 23-May-2023,

Manuscript No. JOB-23-102711;

Editor assigned: 25-May-2023, Pre QC No. JOB-23-102711 (PQ);

Reviewed: 12-Jun-2023, QC No.

JOB-23-102711; **Revised:** 15-Jun-

2023, Manuscript No. JOB-23-

102711 (R); **Published:** 22-Jun-

2023, DOI: 10.4172/2322-

0066.11.2.009

***For Correspondence:**

Malgorzata A. Witek, Department of Chemistry, The University of Kansas, Lawrence, KS 66047, USA

E-mail: mwitek@ku.edu

Citation: Witek MA, et al. Changing the Paradigm in Prognostic Breast Cancer Testing Based on Extracellular Vesicles. RRJ Biol. 2023;11:009

ABOUT THE STUDY

Women with early-stage breast cancer have several options for genomic tests including Oncotype DX®, MammaPrint®, and Prosigna® that can estimate risk of distant recurrence and help determine whether they will benefit from adjuvant chemotherapy, but these tests depend on access to tumor tissue samples [1-3]. Our recently published work on “Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesicles’ mRNA” was driven by a desire to develop a liquid-based biopsy approach to estimate the risk of distant recurrence for breast cancer patients receiving endocrine therapy [4].

The clinical relevance in therapeutic stratifications of different molecular subtypes of breast cancer has been demonstrated [5]. Molecular subtyping in breast cancer looks beyond the common prognostic clinical-pathological parameters (e.g., age, tumor size, presence of node metastases and histological grade) and receptor status (i.e., progesterone, estrogen, and HER2) to make sure breast cancer patients receive proper treatment. One such test is the Prosigna® Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test). Prosigna® is used to estimate the risk of distant recurrence for postmenopausal women within 10 years of diagnosis of early-stage, hormone-receptor-positive disease with up to three positive

Copyright: © 2023 Witek MA, et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

lymph nodes after 5 years of hormonal therapy.

Our study focused on molecular profiling and subtyping of breast cancer patients using a minimally invasive approach. We focused our attention specifically on Extracellular Vesicles (EVs) and their molecular cargo (i.e., exo-mRNA) that can be secured from a simple blood draw. The premise of our research was that EVs carry RNA cargo believed to be associated with the cell-of-origin and thus, have the potential to serve as a liquid biopsy marker for supplying molecular information to identify characteristics of the disease (i.e., precision medicine). EVs were affinity selected by targeting epithelial and mesenchymal surface markers and the harvested exo-mRNA cargo was analyzed using the PAM50® gene panel on the Nanostring nCounter. We also developed a new analysis algorithm (exo- PAM50), which aided in the examination of the exo-mRNA data. Our initial results were very encouraging and suggested that the quantitation of PAM50-based exo-mRNA transcripts collected from both epithelial and mesenchymal EVs could generate profiles with high concordance to tumor tissue-based testing.

Additional studies are required to further validate our exo-mRNA-based PAM50 assay and potentially other clinical approved prognostic tests in breast cancer patients; however, in our work we have demonstrated the feasibility of using novel methods to efficiently isolate exo-biomarkers and their analysis with the validated technologies or clinical lab-developed tests. Liquid biopsy assays will be important in the future as they can be used in the stratification and subtyping of other epithelial cancers. For example, molecular subtypes have been identified for other epithelial malignancies such as pancreatic, colorectal, prostate, bladder, and sub-classification of triple-negative breast cancers [6-10].

Extracellular Vesicles (EVs) have the potential to function as a minimally invasive liquid biopsy marker for delivering molecular information to assist treatment decisions (i.e., precision medicine) since they carry RNA cargo that is thought to be connected with the cell-of-origin. We describe the high-volume production-capable affinity isolation of EV subpopulations using monoclonal antibodies mounted to the surface of a microfluidic chip made of plastic. The efficacy of the EV-Microfluidic Affinity Purification (EV-MAP) chip was established in a proof-of-concept application to give molecular subtyping data for breast cancer patients by isolating EVs derived from two-orthogonal cell types.

ACKNOWLEDGEMENTS

This study was supported by two NIH-funded Centers with dedicated goal and mission to advance precision medicine. The ultimate undertaking of these two entities is to generate novel bioengineering tools and modalities for the efficient and highly specific isolation of liquid biopsy markers (Center of BioModular Multiscale Systems for Precision Medicine, CBM2 at the University of Kansas; P41EB020594) and aid in biomarker discovery and validation (Kansas Institute of Precision Medicine, KIPM at the University of Kansas Medical Center; P20 GM130423).

DISCLOSURES

MAW is a spouse of the employee of BioFluidica, Inc. SAS has equity in BioFluidica, Inc., serves as the CSO and is on the Board of Directors for BioFluidica, Inc. AKG is the co-founder of Sinochips Diagnostics and serves on the scientific advisory board for Sinochips Diagnostics, LLC.

REFERENCES

1. Bartlett JMS, et al. Comparative survival analysis of multiparametric tests- when molecular tests disagree-A TEAM Pathology study. NPJ Breast Cancer. 2021;7:90.
2. Buus R, et al. Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. J Clin Oncol. 2021;39:126-135.
3. Chowdhury A, et al. Evaluation and comparison of different breast cancer prognosis scores based on gene expression data. Breast Cancer Res. 2023;25:17.
4. Hu M, et al. Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesicles' mRNA. Anal Chem. 2023;95:7665-7675.
5. Prat A, et al. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;135:301-306.
6. Guinney J, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-1356.
7. Kamoun A, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420-433.
8. Schoenborn JR, et al. genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 2013;19:4058-4066.
9. Torres C, et al. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med. 2018;50:277-287.
10. Yin L, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020;22:61.